Vorsetuzumab mafodotin

Names

[ CAS No. ]:
1165741-01-4

[ Name ]:
Vorsetuzumab mafodotin

Biological Activity

[Description]:

Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity[1].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> Cell Cycle/DNA Damage >> Microtubule/Tubulin
Signaling Pathways >> Cytoskeleton >> Microtubule/Tubulin

[In Vitro]

Vorsetuzumab mafodotin (SGN-75; 0.01-10000 ng/mL; for 96 h) induces dose-dependent cytotoxicity that is specific with an IC50 of 29 ng/mL[1]. Cell Cytotoxicity Assay[1] Cell Line: SK-OV-3 cells Concentration: 0.01 ng/mL, 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, 10000 ng/mL Incubation Time: 96 h Result: Induced dose-dependent cytotoxicity.

[In Vivo]

Vorsetuzumab mafodotin (SGN-75; 3 mg/kg; four intraperitoneal injections at 4-day interval) significantly reduces median tumour volumes and delays tumour growth[1]. Animal Model: Nude (nu/nu) female mice injected with MiaPaCa-2/CD70 tumour pieces[1] Dosage: 3 mg/kg Administration: Intraperitoneal injection; every 4 days; for a total of four doses Result: Significantly reduced median tumour volumes and delayed tumour growth.

[References]

[1]. M C Ryan, et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer. 2010 Aug 24;103(5):676-84.  

Chemical & Physical Properties

[ Molecular Weight ]:
150 (kDa)

Related Compounds